Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $21

Benzinga Newsdesk www.benzinga.com Positive 72.4%

Neg 0% Neu 0% Pos 72.4%

Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight and raises the price target from $19 to $21.